ENIGMA+: Elucidating Novel Immune and Genomic Markers for ALK
ENIGMA+ is a research study to understand the biology of ALK+ lung cancer. Anyone with ALK+ non-small cell lung cancer is eligible to participate.
Participants consent to provide saliva (spit), tissue from previous biopsies, interview information about the cancer diagnosis, and copies of medical records. A new biopsy is not required. You can participate in this research from your own home without changing your doctor. No test results will be returned to you, this study is for research purposes only.
The study is being led by Jessica J. Lin, MD at the Massachusetts General Hospital in collaboration with our partner organization ALCMI.
To learn more or to enroll, please call 1-888-7-ENIGMA (888-736-4462) or fill out the contact form on this page.
This study is a collaboration between the Addario Lung Cancer Medical Institute and GO2 for Lung Cancer.